Krystal Biotech, Inc. (KRYS) Stock

Krystal Biotech, Inc. (KRYS) is a Healthcare stock trading at $347.56 (as of 2026-06-18), with a market capitalization of $9.11B and a trailing P/E of 41.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on reusable gene therapy approaches to treat serious rare diseases in the United States. It is developing beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa and multiple additional gene therapy candidates across Phase I/II, Phase III, and preclinical stages.

Valuation — source: SEC EDGAR (first-party)
Price$347.56
Market Cap$9.11B
P/E Ratio41.4
EV / EBITDA46.6
Price / Book7.14
Price / Sales21.83
DCF Value (model)$127.00
DCF Upside vs Price-63.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$389.13M
Net Margin52.6%
Return on Equity17.6%
Current Ratio9.46
Revenue Growth (YoY)33.9%
EPS Growth (YoY)126.9%
FCF Growth (YoY)58.5%
Financial Health — source: SEC EDGAR
Altman Z-Score54.91 (safe)
Valuation vs Sector & Industry
Stock P/E41.4
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector97.4%
vs Industry139.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($1.13B)
Institutional Holders Tracked10
Congressional Trades (recent)1
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOKrish S. Krishnan
Employees275
CountryUS
IPO Date2017-09-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Halozyme Therapeutics, Inc. (HALO)
  • Cytokinetics, Incorporated (CYTK)
  • Praxis Precision Medicines, Inc. (PRAX)
  • Nuvalent, Inc. (NUVL)
  • Rhythm Pharmaceuticals, Inc. (RYTM)
  • Kymera Therapeutics, Inc. (KYMR)
  • PTC Therapeutics, Inc. (PTCT)
  • Vaxcyte, Inc. (PCVX)
KRYS earnings history · KRYS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.